Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.62 |
| ▸ | ERN1 | O75460 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | UNG | P13051 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL28325092 | 0.98 | HPGD (0.60) | HPGDERN1LMNAPOLBALDH1A1 | |
| SCHEMBL15650472 | 0.98 | HPGD (0.61) | HPGDERN1LMNAPOLBALDH1A1 | |
| SCHEMBL15652194 | 0.86 | SIGMAR1 (0.55) | HPGDERN1LMNAPOLBUNG | |
| SCHEMBL15172617 | 0.84 | SIGMAR1 (0.61) | HPGDALDH1A1UNGTP53 | |
| SCHEMBL28154929 | 0.84 | UNG (0.51) | HPGDERN1LMNAALDH1A1UNG | |
| SCHEMBL2666919 | 0.84 | ERN1 (0.61) | HPGDERN1ALDH1A1UNGMEN1 | |
| SCHEMBL4383489 | 0.84 | HPGD (0.56) | HPGDERN1POLBALDH1A1UNG | |
| SCHEMBL7127339 | 0.84 | HPGD (0.77) | HPGDLMNAPOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1471431 | 0.83 | L3MBTL3 (0.51) | ERN1ALDH1A1UNGL3MBTL3L3MBTL1 | |
| Ammonia Solution, Strong SCHEMBL28325064 | 0.83 | ERN1 (0.55) | HPGDERN1POLBALDH1A1UNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3860975-B1 | MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE | GLOBAL BLOOD THERAPEUTICS INC (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-110240592-A | (Z) -3- (3- formoxyl benzylidene) piperazinedione compounds and its application in preparation of anti-tumor drugs | 青岛海洋生物医药研究院股份有限公司 | 2019-09-17 | — | — | CN | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-7915420-B2 | Aryl piperidine amides | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-29 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-20080009521-A1 | Aryl Piperidine Amides | HUANG CHARLES Q | 2008-01-10 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| US-7276610-B2 | Aryl piperidine amides | JANSSEN PHARACEUTICA, NV (BE) | 2007-10-02 | — | — | US | disclosed |
| EP-1660472-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005021525-A1 | ARYL PIPERIDINE AMIDES | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049239-A1 | Aryl piperidine amides | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009521-A1 | Aryl Piperidine Amides | BDNF, NTRK2, OPRL1 | HPGD 3042/4885ERN1 2273/4885LMNA 2587/4885 |
| US-20050049239-A1 | Aryl piperidine amides | BDNF, NTRK2, OPRL1 | HPGD 3042/4885ERN1 2273/4885LMNA 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.